A total of 163 (12.3%) patients received an mTOR inhibitor for the management of facial angiofibroma (Fig. 3), however, only 9 (0.7%) patients received systemic mTOR inhibitors exclusively for the management of facial angiofibroma. This evidence concerns the gene MTOR and Adenoma sebaceum.